Antares Pharma, Inc. (ATRS)

[jab91252]

Not much to add tdp, my friend. I believe Wotton provided just a little more color on the midcycle FDA review in that to paraphrase, "we were satisfied with our dialogue and status with the agency" or something to that effect. The other think that stuck out for me was during the Q&A with the BoA moderator was his question about Copaxone and the adaptability with Antares pen injector and Wotton responded matter of factually of the Antares pen capable of delivering that molecule and also commented or eluded to his own knowledge of the most recent 3TW regimen.

The devil is in the details - of which we know very little to next to nothing.

All in all, Antares is confident in their position(s) on many fronts and I see no reason to cast any doubt otherwise!!